These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
146 related items for PubMed ID: 16370391
1. Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer. Kim D, Cheng GZ, Lindsley CW, Yang H, Cheng JQ. Curr Opin Investig Drugs; 2005 Dec; 6(12):1250-8. PubMed ID: 16370391 [Abstract] [Full Text] [Related]
2. The Akt/PKB pathway: molecular target for cancer drug discovery. Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV. Oncogene; 2005 Nov 14; 24(50):7482-92. PubMed ID: 16288295 [Abstract] [Full Text] [Related]
6. Transforming growth factor beta induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells. Wang J, Yang L, Yang J, Kuropatwinski K, Wang W, Liu XQ, Hauser J, Brattain MG. Cancer Res; 2008 May 01; 68(9):3152-60. PubMed ID: 18451140 [Abstract] [Full Text] [Related]
7. Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells. Calleros L, Sánchez-Hernández I, Baquero P, Toro MJ, Chiloeches A. Carcinogenesis; 2009 Oct 01; 30(10):1670-7. PubMed ID: 19700418 [Abstract] [Full Text] [Related]
8. Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors. Porta C, Figlin RA. J Urol; 2009 Dec 01; 182(6):2569-77. PubMed ID: 19836781 [Abstract] [Full Text] [Related]
9. Involvement of Bcl-2 family members, phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Shankar S, Srivastava RK. Int J Oncol; 2007 Apr 01; 30(4):905-18. PubMed ID: 17332930 [Abstract] [Full Text] [Related]
10. Targeting the PI3K-Akt pathway in kidney cancer. Park JY, Lin PY, Weiss RH. Expert Rev Anticancer Ther; 2007 Jun 01; 7(6):863-70. PubMed ID: 17555396 [Abstract] [Full Text] [Related]
11. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC, Mitsiades CS. Cancer Res; 2009 Jul 15; 69(14):5835-42. PubMed ID: 19584292 [Abstract] [Full Text] [Related]
12. Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration. Guerreiro AS, Fattet S, Fischer B, Shalaby T, Jackson SP, Schoenwaelder SM, Grotzer MA, Delattre O, Arcaro A. Clin Cancer Res; 2008 Nov 01; 14(21):6761-9. PubMed ID: 18980969 [Abstract] [Full Text] [Related]
13. PTEN, more than the AKT pathway. Blanco-Aparicio C, Renner O, Leal JF, Carnero A. Carcinogenesis; 2007 Jul 01; 28(7):1379-86. PubMed ID: 17341655 [Abstract] [Full Text] [Related]
14. Low dose leflunomide activates PI3K/Akt signalling in erythroleukemia cells and reduces apoptosis induced by anticancer agents. Leger DY, Liagre B, Beneytout JL. Apoptosis; 2006 Oct 01; 11(10):1747-60. PubMed ID: 16927021 [Abstract] [Full Text] [Related]
15. Human urine extract CDA-2 induces apoptosis of myelodysplastic syndrome-derived MUTZ-1 cells through the PI3K/Akt signaling pathway in a caspase-3-dependent manner. Huang J, Yang M, Liu H, Jin J. Acta Pharmacol Sin; 2008 Aug 01; 29(8):951-64. PubMed ID: 18664328 [Abstract] [Full Text] [Related]
16. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Granville CA, Memmott RM, Gills JJ, Dennis PA. Clin Cancer Res; 2006 Feb 01; 12(3 Pt 1):679-89. PubMed ID: 16467077 [Abstract] [Full Text] [Related]
17. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Generali D, Fox SB, Brizzi MP, Allevi G, Bonardi S, Aguggini S, Milani M, Bersiga A, Campo L, Dionisio R, Vergoni F, Giardini R, Dogliotti L, Bottini A, Harris AL, Berruti A. Clin Cancer Res; 2008 May 01; 14(9):2673-80. PubMed ID: 18451231 [Abstract] [Full Text] [Related]
18. From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy. Georgakis GV, Younes A. Expert Rev Anticancer Ther; 2006 Jan 01; 6(1):131-40. PubMed ID: 16375650 [Abstract] [Full Text] [Related]
19. Inhibition of PI3K/Akt partially leads to the inhibition of PrP(C)-induced drug resistance in gastric cancer cells. Liang J, Ge F, Guo C, Luo G, Wang X, Han G, Zhang D, Wang J, Li K, Pan Y, Yao L, Yin Z, Guo X, Wu K, Ding J, Fan D. FEBS J; 2009 Feb 01; 276(3):685-94. PubMed ID: 19143835 [Abstract] [Full Text] [Related]
20. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J. Cancer Res; 2008 Oct 01; 68(19):8022-30. PubMed ID: 18829560 [Abstract] [Full Text] [Related] Page: [Next] [New Search]